Comparing the current results to its competitors, Theravance Biopharma Inc reported Revenue decrease in the 2 quarter 2026 year on year by -20.86 %, despite the revenue increase by the most of its competitors of 13.08 %, recorded in the same quarter.
Theravance Biopharma inc , slower than the average decrease reported by the company's competitors of -72.87 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -72.87 %
Theravance Biopharma Inc 's Comment on Competition and Industry Peers
The company operates in the respiratory therapeutics market, primarily focusing on acute care settings. Its medicines are commercialized through collaborative partnerships and compete with existing and anticipated market-leading products. Competitors in this sector generally possess greater financial, technical, personnel, and commercial resources. Competitive success relies on delivering effective medicines, retaining qualified personnel, maintaining patent protections and regulatory approvals, and implementing effective commercialization strategies. Notable competitors include AstraZeneca, with Breztri Aerosphere for COPD; Chiesi Farmaceutici, with Trimbow for COPD in Europe; and Novartis, with Enerzair Breezhaler for asthma in Japan. The company's product TRELEGY is the only triple therapy approved in the United States for asthma and competes with these products as well as open triple therapy approaches in COPD and asthma treatment.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Theravance Biopharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Theravance Biopharma inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
